Hospital Da Luz S.A.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Hospital Da Luz S.A. is conducting studies that aim to reduce heart‑related events and improve outcomes for patients with various cardiac conditions. Trials evaluate new lipid‑lowering agents, anti‑inflammatory therapies, and novel anticoagulants to prevent heart failure progression, stroke, and atrial fibrillation complications.
- Heart failure with preserved ejection fraction and systemic inflammation
- Primary prevention of atherosclerotic cardiovascular disease
- Ischemic stroke prevention after acute non‑cardioembolic stroke or high‑risk TIA
- Reducing stroke and systemic embolism risk in atrial fibrillation
- Long‑term impact of inclisiran on major adverse cardiovascular events
These investigations reflect the site’s commitment to advancing cardiovascular care through innovative therapies.
Digestive System Diseases
Research at the internal medicine department focuses on inflammatory bowel conditions, seeking treatments that achieve endoscopic healing and sustained symptom relief.
- Efficacy of a novel oral agent for moderately to severely active ulcerative colitis
- Assessment of endoscopic improvement and remission rates
- Safety profile of emerging therapies in chronic colitis
The trials aim to provide patients with more effective options for managing digestive inflammation.
Neoplasms
The site is engaged in oncology studies targeting both solid tumors and hematologic malignancies, with the goal of extending survival and improving quality of life for cancer patients.
- Advanced ER‑positive, HER2‑negative breast cancer treatment comparisons
- Therapy for unresectable or metastatic melanoma using novel immune agents
- Evaluation of small cell lung cancer regimens versus standard chemotherapy
- Combination chemoradiotherapy for esophageal carcinoma
- Strategies for breast neoplasms with high recurrence risk
These cancer trials reflect a multidisciplinary effort to test new biologics and targeted medicines.
Nervous System Diseases
Clinical investigations address both episodic and chronic neurological disorders, exploring preventive and disease‑modifying approaches.
- Preventive therapy for chronic and episodic migraine comparing novel agents to established treatments
- Long‑term safety of tolebrutinib in relapsing and progressive multiple sclerosis
- Evaluation of central nervous system disease outcomes in broader neuro‑health trials
The research aims to reduce migraine frequency and slow multiple sclerosis progression.
Nutritional and Metabolic Diseases
Studies in this therapeutic area target weight management and metabolic health, especially in younger populations, to curb the growing burden of obesity.
- Pediatric weight‑loss efficacy of semaglutide in children aged 6–12 years
- Impact of lifestyle‑adjunct therapy on obesity and overweight in adults
- Cardiovascular safety assessment of a novel agent in participants with excess body weight
These trials seek to provide sustainable solutions for metabolic disease prevention.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 16 therapeutic areas and 15 of 249 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 243 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 31 by active trials.
- 1Amgen Inc.4active
lock +30 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.12trials
lock +23 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Da Luz S.A.
lock Showing 1 of 115 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 249 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 11 | Unknown | 2017-07-06 | 2026-06-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.